Safety Profile of Innohep [low molecular weight heparins] Versus Subcutaneous Unfractionated Heparin in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis.

Trial Profile

Safety Profile of Innohep [low molecular weight heparins] Versus Subcutaneous Unfractionated Heparin in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2011

At a glance

  • Drugs Heparin; Tinzaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IRIS
  • Sponsors LEO Pharma
  • Most Recent Events

    • 01 Jul 2011 Results published in Thrombosis Research.
    • 15 Apr 2008 Status changed from recruiting to in progress, reported by ClinicalTrials.gov
    • 01 Aug 2007 The low-molecular weight heparin used in this study has been identified as tinzaparin sodium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top